Search Browse Earnings

HUTCHMED (China) Ltd

Nasdaq:HCMOTC:HMDCF

Pharmaceutical Preparations·HONG KONG

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

HUTCHMED (China) Ltd — SlamSEC

Revenue

$838.0M

+96.5% YoY

FY 2025

Adj. EBITDA

$26.6M

3.2% margin

FY 2025

Net Income

$100.8M

12.0% margin

FY 2025

EPS (Diluted)

$0.12

FY 2025

Stock Price

$13.80

-0.4%

2026-03-06

52W Range

$11.51 – $19.50

P/E Ratio

115.0x

Market Cap

$12.0B

Cash

$154.0M

FY 2025

Total Debt

$82.8M

FY 2025

Net Cash

$71.2M

FY 2025

Enterprise Value

$12.0B

Debt / EBITDA

-2.7x

FY 2025

EV / EBITDA

450.2x

Employees

—